- Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living with Duchenne - - Announced in celebration of World Duchenne Awareness Day, grants are designed to fund efforts advancing diversity, equity, inclusion and accessibility within the Duchenne community - BOSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), is a clinicalstage biopharmaceutical company aiming to transform the l ...

Entrada Therapeutics, Inc. (TRDA) came out with quarterly earnings of $1.55 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to loss of $0.78 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 138.46%. A quarter ago, it was expected that this company would post a loss of $0.38 per share when it actually produced earnings of $0.68, delivering a surprise of 278.95%. Over the last four quarters, the ...

Entrada Therapeutics, Inc. (TRDA) closed the last trading session at $16.17, gaining 14.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $20.33 indicates a 25.7% upside potential. However, an impressive consensus price target is not the only factor that indicates a potential upside in TRDA. This view is strengthened by the agreement among analysts that the company will report bet ...

Entrada Therapeutics, Inc. (TRDA) shares rallied 10.4% in the last trading session to close at $17.37. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 0.9% loss over the past four weeks. Last month, the company announced positive preliminary data from its phase I ENTR-601-44-101 study, which evaluated its lead pipeline candidate, ENTR-601-44, as a potential treatment for Duchenne Muscular Dystrophy. Treatment ...

BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinicalstage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that it has entered into a securities purchase agreement with a group of investors for the purchase of 3,367,003 shares of common stock and pre-funded warrants to purchase up to 3,367,003 shares of common stoc ...

Core Viewpoint - Entrada Therapeutics, Inc. has announced a registered direct offering of common stock and pre-funded warrants, aiming to raise approximately $100 million to support its clinical development and research initiatives [4][6]. Group 1: Offering Details - The company has entered into a securities purchase agreement for the purchase of 3,367,003 shares of common stock and pre-funded warrants to purchase an equal number of shares [4]. - The purchase price for the common stock is set at $14.85 per share, while the pre-funded warrants are priced at $14.8499 each [5]. - The offering is expected to close on or about June 25, 2024, pending customary closing conditions [5]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to fund ongoing clinical development for ENTR-601-44 and ENTR-601-45, as well as the initiation of planned Phase 2b clinical trials and a Phase 2 multiple ascending dose trial for ENTR-601-50 [6]. - Additional funds will support research and development across the company's pipeline, including neuromuscular and ocular franchises, with the remainder allocated for working capital and general corporate purposes [6]. Group 3: Company Overview - Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on creating a new class of medicines that target previously inaccessible intracellular sites [9]. - The company is advancing a development portfolio that includes RNA-, antibody-, and enzyme-based programs aimed at treating various diseases, including neuromuscular and ocular conditions [9]. - Its lead oligonucleotide programs are in development for treating Duchenne muscular dystrophy, specifically targeting exon 44, 45, and 50 skipping [9].

– ENTR-601-44 demonstrated significant plasma concentration, muscle concentration and exon skipping, at levels that suggest the potential for a clinically meaningful starting dose in planned upcoming patient trials – "We are excited to present the first clinical data from our Duchenne franchise, led by ENTR-601-44. ENTR601-44 was well tolerated in healthy volunteers and we are pleased to see significant plasma concentration, muscle concentration and exon skipping. We achieved the goals of the ENTR-601-44-10 ...

Shares of Entrada Therapeutics, Inc. (TRDA) have gained 17% over the past four weeks to close the last trading session at $15.32, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $21 indicates a potential upside of 37.1%. The average comprises three short-term price targets ranging from a low of $18 to a high of $25, with a standard deviation of $3.61. While the lowest estimate i ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 10-Q ____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-40969 ___________________ ...

Clinical Trials - The company initiated dosing for the fourth and final cohort of its Phase 1 clinical trial of ENTR-601-44 for DMD, with data readout expected in October 2024[1]. - The company expects to submit regulatory applications in Q4 2024 for independent global Phase 2 clinical development studies for ENTR-601-44 and ENTR-601-45[3]. Financial Performance - Collaboration revenue for Q1 2024 was $59.1 million, a significant increase from $25.3 million in Q1 2023, primarily due to a clinical advancement milestone[6]. - The company reported a net income of $23.5 million for Q1 2024, compared to a net loss of $(6.7) million for the same period in 2023[8]. - Total operating expenses for Q1 2024 were $38.0 million, compared to $31.0 million for the same period in 2023[14]. Cash Position - Cash, cash equivalents, and marketable securities totaled $327.4 million as of March 31, 2024, down from $352.0 million as of December 31, 2023, with a cash runway expected through Q2 2026[5]. - A milestone payment of $75 million from Vertex is expected to be received in Q2 2024, contributing to the company's cash position[4]. - The company is eligible to receive up to $485 million in total from its collaboration with Vertex, including milestones and royalties on future net sales[4]. Expenses - Research and development expenses increased to $28.6 million in Q1 2024 from $23.1 million in Q1 2023, driven by the progression of clinical trials and higher personnel costs[7]. - General and administrative expenses rose to $9.4 million in Q1 2024 from $7.9 million in Q1 2023, mainly due to increased personnel costs[8].